Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Tepotinib

    Client Email Product

    Tepotinib

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    1
    US DMFs Filed

    US DMFs Filed

    0

    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    1
    API REF. PRICE (USD / KG)

    0

    API Market Place

    2
    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    1
    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    1
    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    5.00

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS

    0

    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    8

    USFDA Exclusivities

    2
    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    22
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    Full View ScreenFull Screen View
    Merck to Highlight Data at ESMO with Potential for Impact on Cancer Patients
    Merck to Highlight Data at ESMO with Potential for Impact on Cancer Patients

    https://www.businesswire.com/news/home/20220907005443/en

    BUSINESSWIRE
    07 Sep 2022
    Share Share
    Merck Europe B.V. Tepmetko(tepotinib) Receives Approval in Europe
    Merck Europe B.V. Tepmetko(tepotinib) Receives Approval in Europe

    https://www.ema.europa.eu/en/documents/overview/tepmetko-epar-medicine-overview_en.pdf

    EMA
    05 May 2022
    Share Share
    EC Approves TEPMETKO in Advanced NSCLC with METex14 Skipping Alterations
    EC Approves TEPMETKO in Advanced NSCLC with METex14 Skipping Alterations

    https://www.businesswire.com/news/home/20220217005798/en

    BUSINESSWIRE
    18 Feb 2022
    Share Share
    TEPMETKO Receives Positive CHMP Opinion in Advanced NSCLC
    TEPMETKO Receives Positive CHMP Opinion in Advanced NSCLC

    https://www.businesswire.com/news/home/20211216005685/en

    BUSINESSWIRE
    17 Dec 2021
    Share Share
    MHRA backs Merck’s MET inhibitor Tepmetko
    MHRA backs Merck’s MET inhibitor Tepmetko

    https://www.pharmatimes.com/news/mhra_backs_mercks_met_inhibitor_tepmetko_1380739

    Lucy Parsons PHARMATIMES
    13 Oct 2021
    Share Share
    EMD Serono to Highlights From Oncology Portfolio at WCLC & ESMO 2021
    EMD Serono to Highlights From Oncology Portfolio at WCLC & ESMO 2021

    https://www.businesswire.com/news/home/20210912005053/en

    BUSINESSWIRE
    13 Sep 2021
    Share Share
    AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval
    AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval

    https://www.globenewswire.com/news-release/2021/08/17/2281638/0/en/AmoyDx-Pan-Lung-Cancer-PCR-Panel-Receives-MHLW-Approval-as-Companion-Diagnostic-for-TEPMETKO-tepotinib.html

    GLOBENEWSWIRE
    16 Aug 2021
    Share Share
    Merck’s MET inhibitor tepotinib gains positive opinion from MHRA
    Merck’s MET inhibitor tepotinib gains positive opinion from MHRA

    http://www.pharmatimes.com/news/mercks_met_inhibitor_tepotinib_gains_positive_opinion_from_mhra_1373134

    Lucy Parsons PHARMATIMES
    15 Jul 2021
    Share Share
    FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor
    FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor

    https://www.prnewswire.com/news-releases/fda-approves-tepmetko-as-the-first-and-only-once-daily-oral-met-inhibitor-for-patients-with-metastatic-nsclc-with-metex14-skipping-alterations-301221542.html

    PRNEWSWIRE
    03 Feb 2021
    Share Share
    FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor
    FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor

    https://www.prnewswire.com/news-releases/fda-approves-tepmetko-as-the-first-and-only-once-daily-oral-met-inhibitor-for-patients-with-metastatic-nsclc-with-metex14-skipping-alterations-301221542.html

    PRNEWSWIRE
    03 Feb 2021
    Share Share
    EU to review Merck's targeted lung cancer drug
    EU to review Merck's targeted lung cancer drug

    http://www.pharmatimes.com/news/eu_to_review_mercks_targeted_lung_cancer_drug_1358459

    Selina McKee PHARMATIMES
    28 Nov 2020
    Share Share
    European Medicines Agency Validates Application for Tepotinib
    European Medicines Agency Validates Application for Tepotinib

    https://www.pharmiweb.com/press-release/2020-11-27/european-medicines-agency-validates-application-for-tepotinib-for-the-treatment-of-advanced-nsclc-wi

    PHARMIWEB
    26 Nov 2020
    Share Share
    FDA starts quick review of Merck’s MET-targeting lung cancer drug
    FDA starts quick review of Merck’s MET-targeting lung cancer drug

    https://pharmaphorum.com/news/fda-starts-quick-review-of-mercks-met-targeting-lung-cancer-drug/

    Phil Taylor PHARMAPHORUM
    28 Aug 2020
    Share Share
    Bexarotene combined with lapatinib for the treatment of Cushing’s disease
    Bexarotene combined with lapatinib for the treatment of Cushing’s disease

    https://www.nature.com/articles/s41392-020-00284-7

    NATURE
    28 Aug 2020
    Share Share
    US FDA accepts Merck’s NDA for tepotinib and grants priority review status
    US FDA accepts Merck’s NDA for tepotinib and grants priority review status

    http://www.pharmabiz.com/NewsDetails.aspx?aid=130668&sid=2

    PHARMABIZ
    26 Aug 2020
    Share Share
    FDA Accepts Filing of New Drug Application for Tepotinib for the Treatment
    FDA Accepts Filing of New Drug Application for Tepotinib for the Treatment

    https://www.prnewswire.com/news-releases/fda-accepts-filing-of-new-drug-application-for-tepotinib-for-the-treatment-of-patients-with-metastatic-nsclc-with-metex14-skipping-alterations-301117906.html

    PRNEWSWIRE
    24 Aug 2020
    Share Share
    Novartis pulls ahead of Merck in MET-positive lung cancer race
    Novartis pulls ahead of Merck in MET-positive lung cancer race

    http://www.pmlive.com/pharma_news/novartis_pulls_ahead_of_merck_in_met-positive_lung_cancer_race_1325056

    Phil Taylor PMLIVE
    11 Feb 2020
    Share Share
    Merck presented Data on Tepotinib for NSCLC at ESMO Asia 2019
    Merck presented Data on Tepotinib for NSCLC at ESMO Asia 2019

    https://www.biospectrumasia.com/news/34/14964/merck-presented-data-on-tepotinib-for-nsclc-at-esmo-asia-2019.html

    BIOSPECTRUM ASIA
    27 Nov 2019
    Share Share
    Merck KGaA, Darmstadt, Germany, Announces Orphan Drug Designation for Tepotinib
    Merck KGaA, Darmstadt, Germany, Announces Orphan Drug Designation for Tepotinib

    https://www.biospace.com/article/releases/merck-kgaa-darmstadt-germany-announces-orphan-drug-designation-for-investigational-therapy-tepotinib-in-patients-with-nsclc-harboring-met-gene-alterations/?s=95

    BIOSPACE
    19 Nov 2019
    Share Share
    Merck KGaA touts FDA 'breakthrough' status
    Merck KGaA touts FDA 'breakthrough' status

    https://endpts.com/merck-kgaa-touts-fda-breakthrough-status-blockbuster-potential-in-bid-to-investors/

    Jason Mast ENDPOINTS NEWS
    12 Sep 2019
    Share Share
    MET inhibitors from Incyte/Novartis and Germany's Merck face off
    MET inhibitors from Incyte/Novartis and Germany's Merck face off

    https://endpts.com/asco19-met-inhibitors-from-incyte-novartis-and-germanys-merck-face-off-for-rare-subset-of-nsclc-patients/

    Natalie Grover ENDPTS
    05 Jun 2019
    Share Share
    Merck KGaA, Darmstadt, Germany Provides Update on Tepotinib Phase II Results
    Merck KGaA, Darmstadt, Germany Provides Update on Tepotinib Phase II Results

    https://www.prnewswire.com/news-releases/merck-kgaa-darmstadt-germany-provides-update-on-tepotinib-phase-ii-results-in-advanced-hepatocellular-carcinoma-685120081.html

    PR NEWSWIRE
    11 Jun 2018
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search